Preliminary unaudited Q4 2025 consolidated revenues are expected to be at least $261 million, an increase from $248.0 million in Q4 2024. Preliminary unaudited full-year 2025 consolidated revenues are expected to be at least $1.016 billion, an increase from $948.9 million in 2024. Preliminary unaudited Q4 2025 Adjusted EBITDA is expected to be at least $63 million, an increase from $53.7 million in Q4 2024. Preliminary unaudited full-year 2025 Adjusted EBITDA is expected to be at least $229 million, an increase from $200.8 million in 2024. The Q4 2025 net loss is expected to be not larger than $25.4 million, compared to $25.1 million in Q4 2024. The full-year 2025 net loss is expected to be not larger than $43.8 million, a decrease from $94.1 million in 2024. Lumexa Imaging completed an initial public offering (IPO) in Q4 2025. The company meaningfully reduced leverage and refinanced remaining debt at a more favorable rate in Q4 2025. In Q4 2025, 3 wholly owned de novo centers were opened, and one site was acquired. For the full year 2025, 9 de novo centers were opened (6 wholly owned and 3 through joint ventures), and one site acquisition was completed. Consolidated total procedures increased 4.6% year-over-year to 2,418,096 in 2025. System-wide total procedures increased 3.4% year-over-year to 3,972,228 in 2025. An AI-powered Breast Arterial Calcification pilot was successfully launched in New Jersey, with over 12% of screening mammography patients electing to add the assessment.